| 3.495 0.095 (2.79%) | 09-16 11:52 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.1 | 1-year : | 11.21 |
| Resists | First : | 6.94 | Second : | 9.6 |
| Pivot price | 3.46  |
|||
| Supports | First : | 2.64 | Second : | 2.19 |
| MAs | MA(5) : | 3.47 |
MA(20) : | 3.36 |
| MA(100) : | 3.57  |
MA(250) : | 10.35 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 11.5 |
D(3) : | 11.9 |
| RSI | RSI(14): 51.7 |
|||
| 52-week | High : | 31.79 | Low : | 2.64 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CLGN ] has closed above bottom band by 47.7%. Bollinger Bands are 5.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.55 - 3.58 | 3.58 - 3.6 |
| Low: | 3.31 - 3.34 | 3.34 - 3.36 |
| Close: | 3.36 - 3.41 | 3.41 - 3.44 |
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside developing solutions for medical aesthetics. All of CollPlant's offerings are underpinned by its proprietary plant-based genetic engineering technology, which facilitates the production of recombinant type I human collagen. Its diverse product portfolio encompasses BioInks engineered for 3D tissue and organ fabrication; dermal and soft tissue fillers designed to diminish wrinkles; and innovative breast implants, both 3D bioprinted and injectable, aimed at promoting breast tissue regeneration. CollPlant also provides a 3D bioprinted regenerative soft tissue matrix. Specialized products include VergenixSTR, a soft tissue repair matrix targeting tendinopathy, and VergenixFG, an advanced wound care treatment for deep surgical incisions and persistent wounds such as diabetic, venous, and pressure ulcers, burns, and bedsores. The company maintains strategic collaboration agreements with numerous partners, including 3D Systems Corporation, CellInk (a BICO Group company), the Advanced Regenerative Manufacturing Institute, the RegenMed Development Organization, Israel's Technion Institute of Technology, AbbVie, and STEMCELL. Established in Rehovot, Israel, in 2004, the company was formerly known as CollPlant Holdings Ltd. before adopting its current name in June 2019.
Thu, 10 Sep 2026
CollPlant to Host LightSolver Investor Webinar on September 17, 2026 - TradingView
Thu, 10 Sep 2026
A new kind of computer uses light to calculate. LightSolver will explain it Sept. 17. - Stock Titan
Fri, 04 Sep 2026
COLLPLANT APPOINTS DR. RUTI BEN SHLOMI TO ITS BOARD OF DIRECTORS FOLLOWING CLOSING OF LIGHTSOLVER ACQUISITION - PR Newswire
Thu, 03 Sep 2026
CollPlant (CLGN) moves into photonic computing with LightSolver acquisition - Stock Titan
Thu, 03 Sep 2026
A company working on 3D-printed organs now owns a laser-powered computing business - Stock Titan
Tue, 01 Sep 2026
Reverse split ahead for CollPlant (NASDAQ: CLGN) to help keep its Nasdaq listing - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 856090 (%) |
| Held by Institutions | 24.8 (%) |
| Shares Short | 2 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.207e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 267.1 % |
| Return on Equity (ttm) | -61.4 % |
| Qtrly Rev. Growth | 389000 % |
| Gross Profit (p.s.) | -130.28 |
| Sales Per Share | -205.4 |
| EBITDA (p.s.) | -775676 |
| Qtrly Earnings Growth | -10.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.75 |
| Dividend | 0 |
| Forward Dividend | 2190 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|